Tenaya Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

• Tenaya Therapeutics Inc TNYA.OQ reported a quarterly adjusted loss of 14 cents​​ per share for the quarter ended June 30, higher than the same quarter last year, when the company reported EPS of -34 cents. The mean expectation of nine analysts for the quarter was for a loss of 25 cents per share. Wall Street expected results to range from -71 cents to -11 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Tenaya Therapeutics Inc's reported EPS for the quarter was a loss of 14 cents​.

• The company reported a quarterly loss of $23.28 million.

• Tenaya Therapeutics Inc shares had risen by 13.8% this quarter and lost 51.4% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 48% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Tenaya Therapeutics Inc is $5.00, about 86.5% above its last closing price of $0.67

This summary was machine generated from LSEG data August 6 at 10:38 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)